<Page>

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                  Form 10K-SB/A

 [x] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
     1934
     For the fiscal year ended December 31, 2000

 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
     OF 1934
     For the transition period from       to

     Commission file number: 000-26807


                                   CytoGenix, Inc.
                   (Name of Small Business Issuer in its charter)

                  Nevada                              76-0484097
      (State or other jurisdiction of    (I.R.S. Employer Identification No.)
       incorporation or organization)

            9881 South Wilcrest, Houston, Texas               77099
          (Address of principal executive offices)          (Zip Code)

          Issuer's telephone number, including area code (281) 988-6118

           Securities to be registered under Section 12(b) of the Act:

        Title of each class                     Name of each exchange on which
        to be so registered                      each class to be registered
                NA                                             NA

           Securities to be registered under Section 12(g) of the Act:

                     Common Stock, par value $.001 per share
                                (Title of class)

        Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes [X] No [ ]

        Indicate by check mark if disclosure of delinquent filers pursuant to
Item 405 of Regulation S-K is not contained herein, and will not be contained,
to the best of registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-KSB or any
amendment to this Form 10-KSB. [ ]

        Issuer's revenues for the fiscal year ended December 31, 2000 were
$881.

        As of March 31, 2001 the aggregate market value of the registrant's
common stock (based on the closing sales price for the common stock as reported
on the OTC Bulletin Board on such date) held by non-affiliates of the registrant
was approximately $11,649,000 (Aggregate market value has been estimated solely
for the purpose of this report. For the purpose of this report it has been
assumed that all officers and directors are affiliates of the registrant. The
statement made herein shall not be construed as an admission for the purpose of
determining the affiliate status of any person.) As of March 31, 2001 the
registrant had 35,121,928 shares of common stock issued and outstanding.

        Transitional small Business Disclosure Format (check one): Yes__  No _X_

        Documents incorporated by reference:

        None.
<Page>


AMENDMENT NO. 1 TO ANNUAL REPORT ON FORM 10-K

CytoGenix, Inc. ("CytoGenix" or "the Company"), a development stage
biotechnology company, hereby amends and supplements its Annual Report on Form
10-KSB as originally filed by the Company on April 17, 2001 solely for the
purpose of supplementing the disclosure previously made in Item 3 of Part I of
Form 10-KSB and to file as exhibits pursuant to Item 9 of Part III of Form
10-KSB the documents described in that disclosure.

                                     PART I

ITEM 3: LEGAL PROCEEDINGS

ARGYLL DISPUTE

Argyll Scientific, L.L.C. ("Argyll") has asserted, in a letter to the Company
dated March 8, 2001, that the Company owes Argyll (i) 44,949.593 shares of
common stock of the Company pursuant to a Stock Rights Agreement, dated
effective as of March 10, 2000, between Argyll and the Company (the "Stock
Rights Agreement") and (ii) 16,667 shares of the common stock of the Company and
$25,000 (or shares of common stock of the Company having a fair market value
equal to that amount) pursuant to a Research and Development Agreement, dated
effective as of March 10, 2000, between Argyll and the Company (the "Research
and Development Agreement"). The Company strenuously denies any wrongdoing and
intends to vigorously defend against the claims, if any, made by Argyll. In
addition, the Company has delivered notices of termination of the Research and
Development Agreement to Argyll.


Although both the Stock Rights Agreement and the Research and Development
Agreement are dated effective as of March 10, 2000, neither agreement was
delivered to Argyll after being signed by the Company until September 21, 2000,
which is the date upon which those agreements became effective. In addition, on
that date, the Company delivered to Argyll a warrant to acquire 1,590,676 shares
of common stock of the Company at an exercise price of $5.00 per share. The
exercise period for this warrant ends on March 10, 2005.


ITEM 13: EXHIBITS AND REPORTS ON FORM 8-K
         (a)      Exhibits.

<Table>
<Caption>
                  EXHIBIT
                  NUMBER                             DESCRIPTION
                  -------                            -----------
                  <S>               <C>     <C>
                  3.1*              -----   Articles of Incorporation of Cryogenic Solutions,
                                            Inc. (incorporated by reference to Exhibit 3.1 to the registrant's
                                            registration statement on Form 10-SB, as amended (File No.
                                            000-26807), filed with the Securities & Exchange Commission initially
                                            on July 23, 1999 (the "Form 10-SB")).

                  3.2*              -----   Certificate of Amendment dated November 1, 1995


                                                        2
<Page>


                                            of Articles of Incorporation of Cryogenic Solutions, Inc.
                                            (incorporated by reference to Exhibit 3.2 of the Form 10-SB).

                  3.3*              -----   Certificate of Amendment dated January 13, 2000
                                            of Articles of Incorporation of CytoGenix, Inc. (incorporated by
                                            reference to Exhibit 3.3 of the Form 10-SB).

                  3.4*              -----   Bylaws of Cryogenic Solutions, Inc. (incorporated
                                            by reference to Exhibit 3.4 of the Form 10-SB).

                  4.1               ------  Warrant to acquire 1,590,676 shares of common stock of
                                            CytoGenix, Inc., dated March 10, 2000, issued to Argyll
                                            Scientific, LLC.

                  10.1*             -----   Employment Agreement dated September 1, 1999
                                            between Cryogenic Solutions, Inc. and Malcolm H. Skolnick
                                            (incorporated by reference to Exhibit 10.2 of the Form 10-SB).

                  10.2*             -----   License Agreement dated February 3, 2000,
                                            between CytoGenix, Inc. and PharmaGenix, LLC. (incorporated by
                                            reference to Exhibit 10.3 of the Form 10-SB).

                  10.3*             -----   Technology Transfer Agreement dated June 26,
                                            1998 between Cryogenic Solutions, Inc. and InGene, Inc. (incorporated
                                            by reference to Exhibit 10.4 of the Form 10-SB).

                  10.4*             -----   Employment Agreement dated February 1, 2000
                                            between CytoGenix, Inc. and Lawrence Wunderlich (incorporated by
                                            reference to Exhibit 10.5 of the Form 10-SB).

                  10.5*             -----   Employment Agreement dated February 9, 2000
                                            between CytoGenix, Inc. and Dell Gibson (incorporated by reference to
                                            Exhibit 10.6 of the Form 10-SB).

                  10.6*             -----   Sponsored Research Agreement between
                                            CytoGenix, Inc. and Baylor College
                                            of Medicine as of March 1, 2000
                                            (incorporated by reference to
                                            Exhibit 10.7 of the Form 10-SB).


                                                        3
<Page>


                  10.7*             -----   Employment Agreement dated September 1, 2000
                                            between CytoGenix, Inc. and Jonathan Elliston (incorporated by
                                            reference to Exhibit 10.8 of the Form 10-SB).

                  10.8              -----   Research and Development Agreement dated
                                            effective as of March 10, 2000 between CytoGenix, Inc. and Argyll
                                            Scientific, LLC.

                  10.9              -----   Stock Rights Agreement dated effective as of
                                            March 10, 2000 between CytoGenix, Inc. and Argyll Scientific, LLC.

                  16.1*             -----   Letter re: change in certifying accountant
                                            (incorporated by reference to
                                            Exhibit 16 to the registrant's
                                            Current Report on Form 8-K/A filed
                                            with the Securities & Exchange
                                            Commission on April 12, 2001).
</Table>

----------------------
         *Incorporated by reference as indicated.

         (b)      Reports on Form 8-K.

         None.
















                                                      4
<Page>



                                   SIGNATURES

In accordance with Section 13 or 15(d) Exchange Act, the registrant caused this
report to be signed on its behalf by the undersigned, thereunto duly authorized.

                                       CYTOGENIX, INC.


                                       By: /s/ Malcolm Skolnick
                                          --------------------------------------
                                           Malcolm Skolnick, Ph.D.
                                           President and Chief Executive Officer
Date: September 24, 2001






















                                      5